<DOC>
	<DOCNO>NCT02177487</DOCNO>
	<brief_summary>Study assess safety six month open-label , treatment fix dose combination telmisartan 80 mg plus hydrochlorothiazide 12.5 mg subset patient mild-to-moderate hypertension complete eight week randomize , double blind 502.261 study .</brief_summary>
	<brief_title>Safety Evaluation Telmisartan Plus Hydrochlorothiazide Patients With Mild-to-Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>All patient randomize complete study visit precede doubleblind trial fix dose combination ( 502.261 ) meet follow criterion : Patients control telmisartan 80 mg monotherapy final visit ( Visit 6 ) 502.261 study Patients able provide write informed consent Patients able enter study immediately upon completion precede doubleblind trial fix dose combination ( 502.261 ) Patients exclusion criterion ( except criterion 1 , 19 20 ) , define precede study ( 502.261 ) : Premenopausal woman ( last menstruation ≤ 1 year prior start screen ) surgically sterile ( hysterectomy , tubal ligation ) NOT practice acceptable mean birth control NOT plan continue use acceptable method throughout study . Acceptable method birth control include intrauterine device ( IUD ) , oral , implantable injectable contraceptive Any woman : positive serum pregnancy test screening ( Visit 1 ) baseline ( Visit 4 ) positive urine pregnancy test prior take first dose openlabel medication ( Visit 2 ) nursing Hepatic and/or renal dysfunction define follow laboratory parameter : SGPT ( ALT ) ( serum glutamate pyruvate transaminase ) SGOT ( AST ) ( serum glutamate oxaloacetate transaminase ) great two time upper limit normal Serum creatinine &gt; 2.3 mg/dL Clinically relevant sodium depletion , hyperkalemia , hypokalemia baseline Known suspect secondary hypertension Bilateral renal artery stenosis ; renal artery stenosis solitary kidney ; postrenal transplant patient , presence one functioning kidney Congestive heart failure ( CHF ) ( NYHA ( New York Heart Association ) class CHF IIIIV ) Unstable angina within past three month Stroke within past six month Myocardial infarction cardiac surgery within past three month PTCA ( percutaneous transluminal coronary angioplasty ) within past three month History angioedema Sustained ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine investigator Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve Administration digoxin digitalistype drug Patients insulin treat Type II diabetes mellitus whose diabetes stable control least past three month define HbA1C ≥ 10 % Known drug alcohol dependency within past one year period Known hypersensitivity component formulation Any clinical condition , opinion investigator , would allow safe completion protocol safe administration trial medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>